Recombinant Human GM-CSF

Phase 3Small molecule

EEastern Cooperative Oncology Group

Recombinant Human GM-CSF is one of 77 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

103

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Human Papilloma Virus InfectionActive, not recruiting

Malignant MelanomaActive, not recruiting

Melanoma of Unknown PrimaryActive, not recruiting

Human Papillomavirus-Related CarcinomaActive, not recruiting

Neuroendocrine TumorActive, not recruiting

Differentiated Thyroid CarcinomaRecruiting

PapillomaActive, not recruiting

Allogeneic Hematopoietic Stem Cell Transplant RecipientActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Human Papilloma Virus InfectionPhase 2

Active, not recruiting

Malignant MelanomaPhase 2

Active, not recruiting

Melanoma of Unknown PrimaryPhase 3

Active, not recruiting

Human Papillomavirus-Related CarcinomaPhase 2

Active, not recruiting

Neuroendocrine TumorPhase 3

Active, not recruiting

Differentiated Thyroid CarcinomaPhase 2

Recruiting

PapillomaPhase 3

Active, not recruiting

Allogeneic Hematopoietic Stem Cell Transplant RecipientPhase 3

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

22 2

Rubraca

Bristol-Myers Squibb

Phase 3

9 3

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

4 4

Acetylsalicylic Acid

Bayer

Phase 3

2 5

Recombinant Human GM-CSF

EEastern Cooperative Oncology Group

Phase 3

8 6

Provenge

PProstate Oncology Specialists, Inc.

Phase 3

21 7

AAA817

Novartis

Phase 3

1 8

Lupron

Radiation Therapy Oncology Group

Phase 3

6 9

SHR3680

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

5 10

Trexall

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

ApprovedActive, not recruiting

Allogeneic Hematopoietic Stem Cell Transplant Recipient

NCT03023631

Q4 2026

Phase 2Recruiting

Differentiated Thyroid Carcinoma

NCT06440850

Phase 2Active, not recruiting

Prostate Cancer

NCT03899987

Active, not recruiting

Effectiveness

NCT06243666

ApprovedActive, not recruiting

Human Papillomavirus-Related Cervical Carcinoma

NCT05237947

Q1 2027

Phase 2Active, not recruiting

Human Papillomavirus-Related Carcinoma

NCT02568566

Clinical

Trials by Indication[1]

Prostate Cancer8 trials

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00108732·50 enrolled

Sequential Vaccinations in Prostate Cancer Patients

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00060528·32 enrolled

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Active, not recruiting·RRoswell Park Cancer Institute·Phase 2·NCT03899987·12 enrolled

Show 5 more trials

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01145508·10 enrolled

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020254

A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00096551·21 enrolled

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00005039·86 enrolled

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00450619·44 enrolled

Melanoma7 trials

Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

Completed·WWilliam Carson·N/A·NCT01460875·34 enrolled

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

Completed·—·Phase 1·NCT00498979·22 enrolled

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003789·216 enrolled

Show 4 more trials

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00003339·48 enrolled

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00031733·60 enrolled

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT04093323·1 enrolled

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00026143·60 enrolled

Metastatic Melanoma7 trials

Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma

Completed·UUniversity of California, San Diego·Phase 1·NCT00398450·12 enrolled

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Completed·UUniversity of Chicago·Phase 1/2·NCT00002952·20 enrolled

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01307618·10 enrolled

Show 4 more trials

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00022438

Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004148·12 enrolled

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00087373·28 enrolled

Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054535

Breast Cancer6 trials

Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation

Unknown status·—·Phase 1·NCT00003412·35 enrolled

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00052351

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00048893·37 enrolled

Show 3 more trials

Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00004893·5 enrolled

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT04081389·9 enrolled

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00071942·22 enrolled

Lymphoma5 trials

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00003210·105 enrolled

Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Completed·MMayo Clinic·Phase 1·NCT00004260

Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00003575·40 enrolled

Show 2 more trials

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00026182·99 enrolled

Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

Terminated·TThe Cleveland Clinic·Phase 1·NCT00311558·18 enrolled

49 more indications

Kidney Cancer5 trials

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004244·30 enrolled

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00217542·42 enrolled

Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00101114·55 enrolled

Show 2 more trials

Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery

Completed·—·Phase 2·NCT01158534·17 enrolled

Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00126594·80 enrolled

Papilloma4 trials

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT03728881·1,240 enrolled

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)

Unknown status·JJun Zhang··NCT04704908·979 enrolled

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

Completed·XXiamen University·Phase 3·NCT04782895·488 enrolled

Show 1 more trial

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 4·NCT03180034·27,945 enrolled

Metastatic Prostate Cancer4 trials

Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Completed·UUniversity of Chicago·Phase 2·NCT00015977·13 enrolled

Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Terminated·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00176527·40 enrolled

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004029·46 enrolled

Show 1 more trial

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00045227

Metastatic Cancer3 trials

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00217373·33 enrolled

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00028496·48 enrolled

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

Completed·HH. Kim Lyerly·Phase 1·NCT00128622·24 enrolled

Vaccine3 trials

Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00009958·42 enrolled

The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Unknown status·JJun Zhang··NCT05045755·1,339 enrolled

The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Unknown status·JJun Zhang··NCT04969445·647 enrolled

Mycosis Fungoides2 trials

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00052377·46 enrolled

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT04185220·6 enrolled

Non-Small Cell Lung Cancer2 trials

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01727076·20 enrolled

Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

Completed·NNational Cancer Institute (NCI)·N/A·NCT00091039

Advanced Cancer2 trials

Interleukin-12 in Treating Patients With Advanced Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003330·54 enrolled

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003451·40 enrolled

Interleukin2 trials

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004074·15 enrolled

Interleukin-12 in Treating Patients With Cancer in the Abdomen

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00003046·29 enrolled

Multiple Myeloma2 trials

Interleukin-12 in Treating Patients With Multiple Myeloma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003149·40 enrolled

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002556·312 enrolled

Head and Neck Cancer2 trials

Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer

Completed·NNYU Langone Health·N/A·NCT00899821

Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer

Completed·NNational Institute on Deafness and Other Communication Disorders (NIDCD)·Phase 1·NCT00021424

Human Papillomavirus-Related Carcinoma2 trials

A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, A Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05985681·18 enrolled

A Prospective, Single-arm, Open-label, Non-randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-booster Dosing Schedule Among 9-11 Year-old Girls and Boys

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02568566·201 enrolled

Psoriasis1 trial

Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001797·36 enrolled

Antibody1 trial

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

Active, not recruiting·XXiamen University··NCT06197802·392 enrolled

Differentiated Thyroid Carcinoma1 trial

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Recruiting·—·Phase 2·NCT06440850·21 enrolled

Bladder Carcinoma1 trial

Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00072137·21 enrolled

Triple-Negative Breast Cancer1 trial

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT03599453·8 enrolled

Metastatic Colorectal Cancer1 trial

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00088933·60 enrolled

Thyroid Cancer1 trial

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00085293·12 enrolled

Neuroblastoma1 trial

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00054405·40 enrolled

Metastasis1 trial

Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00081848·12 enrolled

Colorectal Cancer1 trial

Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver

Completed·RRoswell Park Cancer Institute·Phase 2·NCT03403634·19 enrolled

Metastatic Solid Tumors1 trial

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00030693·42 enrolled

Liposomal Doxorubicin1 trial

Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020449

Primary Peritoneal Cancer1 trial

Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00016289·30 enrolled

Recurrent Cancer1 trial

Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003017

Vaccine Response1 trial

Vaccine Response With NT-I7

Withdrawn·NNational Cancer Institute (NCI)·Phase 1·NCT04054752

Effectiveness1 trial

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Active, not recruiting·XXiamen University··NCT06243666·2,188 enrolled

Hematologic Cancer1 trial

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

Completed·IIndiana University School of Medicine·Phase 1·NCT00003107

Clinical Trial1 trial

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

Completed·SShanghai Zerun Biotechnology Co.,Ltd·Phase 3·NCT04965350·1,100 enrolled

Patients With Solid Tumors1 trial

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00028535·18 enrolled

HPV Vaccine1 trial

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

Terminated·FFred Hutchinson Cancer Center·Phase 4·NCT03051516·188 enrolled

Uveal Melanoma1 trial

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Completed·—·Phase 2·NCT01100528·38 enrolled

Patients With Advanced Solid Tumors1 trial

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00005604·25 enrolled

Advanced Solid Tumors1 trial

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT04574583·12 enrolled

Cervical Lesion1 trial

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV

Completed·AAIDS Malignancy Consortium·Phase 3·NCT03284866·536 enrolled

Liver Cancer1 trial

Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery

Unknown status·NNational Cancer Centre, Singapore·Phase 2·NCT00471484·54 enrolled

COVID-191 trial

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Terminated·RRoswell Park Cancer Institute·Phase 1/2·NCT04379518·4 enrolled

Ovarian Cancer1 trial

Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003439·36 enrolled

Human Papilloma Virus Infection1 trial

Immunogenicity of Nonavalent HPV Vaccine Administered Prior to Renal Transplantation in Adults: A Prospective, Single-Arm, Multi-Center Clinical Trial

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03036930·51 enrolled

Melanoma of Unknown Primary1 trial

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT01274338·1,673 enrolled

Solid Tumor1 trial

A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01875601·16 enrolled

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02506153·1,301 enrolled

Neuroendocrine Tumor1 trial

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT00569127·427 enrolled

Recurrent Melanoma1 trial

A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01708941·88 enrolled

Allogeneic Hematopoietic Stem Cell Transplant Recipient1 trial

Human Papillomavirus Antibody Response After GARDASIL 9 Vaccination in Patients After Allogeneic Stem Cell Transplantation

Active, not recruiting·MM.D. Anderson Cancer Center·Approved·NCT03023631·48 enrolled

HIV infection1 trial

Multicenter, Randomized, Open-Label Trial in Children and Adolescents to Establish Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV

Completed·FFred Hutchinson Cancer Center·Approved·NCT04265950·97 enrolled

Human Papillomavirus-Related Cervical Carcinoma1 trial

Single-Dose HPV Vaccination Among Young Adult Women in Costa Rica: the PRISMA-ESCUDDO Trial (PRevencIón Del Cáncer Cervical Con Una Sola Dosis de Vacuna Contra VPH en Mujeres Adultas Jóvenes)

Active, not recruiting·NNational Cancer Institute (NCI)·Approved·NCT05237947·5,000 enrolled

Malignant Melanoma1 trial

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT00539591·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 103 trial records for Recombinant Human GM-CSF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Human GM-CSF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Human GM-CSF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEastern Cooperative Oncology Group

Recombinant Human GM-CSF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Trials by Indication[1]

Prostate Cancer8 trials

Melanoma7 trials

Metastatic Melanoma7 trials

Breast Cancer6 trials

Lymphoma5 trials

Kidney Cancer5 trials

Papilloma4 trials

Metastatic Prostate Cancer4 trials

Metastatic Cancer3 trials

Vaccine3 trials

Mycosis Fungoides2 trials

Non-Small Cell Lung Cancer2 trials

Advanced Cancer2 trials

Interleukin2 trials

Multiple Myeloma2 trials

Head and Neck Cancer2 trials

Human Papillomavirus-Related Carcinoma2 trials

Psoriasis1 trial

Antibody1 trial

Differentiated Thyroid Carcinoma1 trial

Bladder Carcinoma1 trial

Triple-Negative Breast Cancer1 trial

Metastatic Colorectal Cancer1 trial

Thyroid Cancer1 trial

Neuroblastoma1 trial

Metastasis1 trial

Colorectal Cancer1 trial

Metastatic Solid Tumors1 trial

Liposomal Doxorubicin1 trial

Primary Peritoneal Cancer1 trial

Recurrent Cancer1 trial

Vaccine Response1 trial

Effectiveness1 trial

Hematologic Cancer1 trial

Clinical Trial1 trial

Patients With Solid Tumors1 trial

HPV Vaccine1 trial

Uveal Melanoma1 trial

Patients With Advanced Solid Tumors1 trial

Advanced Solid Tumors1 trial

Cervical Lesion1 trial

Liver Cancer1 trial

COVID-191 trial

Ovarian Cancer1 trial

Human Papilloma Virus Infection1 trial

Melanoma of Unknown Primary1 trial

Solid Tumor1 trial

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

Neuroendocrine Tumor1 trial

Recurrent Melanoma1 trial

Allogeneic Hematopoietic Stem Cell Transplant Recipient1 trial

HIV infection1 trial

Human Papillomavirus-Related Cervical Carcinoma1 trial

Malignant Melanoma1 trial

References

Drug Info

Quick Facts

Related News